Author:
Tsuji Takayuki,Matsuda Satoru,Sato Yuta,Tanaka Koji,Sasaki Ken,Watanabe Masaya,Hamai Yoichi,Nasu Motomi,Saze Zenichiro,Nakashima Yuichiro,Nomura Motoo,Yamamoto Shun,Booka Eisuke,Ishiyama Koshiro,Bamba Takeo,Sakanaka Katsuyuki,Tsushima Takahiro,Takeuchi Hiroya,Kato Ken,Kawakubo Hirofumi
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. World Health Organization. GLOBOCAN Database. International Agency for Research on Cancer; 2020. Available at: https://gco.iarc.fr/.
2. Ministry of Health, Labour, and Welfare. Number and rate of deaths by sex by simple cause of death classification; 2020. Available at: https://www.mhlw.go.jp/toukei/list/81-1a.html.
3. Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020;31:228–35.
4. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:34–43.
5. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.